Transforming How the World Makes Chemicals
Innovative Bio-Based Specialty Chemicals for a Healthier Future
At DMC Biotechnologies, we are revolutionizing the specialty chemical industry by offering sustainable, bio-based ingredients that meet the highest standards of safety, health, and environmental responsibility.
Our pioneering Dynamic Metabolic Control™ technology delivers reliable, cost-effective, and scalable products to meet the growing demands of the market.
OUR PRODUCTS
Our first generation of products showcases the power of our technology platform to produce sustainable, affordable chemicals for a wide range of markets. With a strong pipeline of innovative products already in place and more in development, we are actively transforming the landscape of sustainable chemical production.
DIETARY SUPPLEMENTS & NUTRACEUTICALS
COSMETIC ACTIVES
BIO-BASED CHEMICALS & MONOMERS
COLLABORATING WITH DMC
Go from concept to commercial faster with our standardized, scalable, and proven technology platform that’s Made to Scale™.
DEVELOPMENT
EFFICIENCY
Go from concept to commercial faster with our standardized, scalable, and proven technology platform.
SUSTAINABLE
PRODUCTION
Our L-alanine production in Europe will reduce CO2 emissions by over 90%, compared to imported L-alanine. That’s equivalent to removing more than 60,000 cars from the road, annually.
SUPPLY CHAIN
SECURITY
Cost-competitive, local production using agricultural feedstocks enables our customers to diversify their supply chain, making them more resilient to the next global shift.
PARTNER WITH DMC ON YOUR NEXT PRODUCT
DMC’s innovative technology and metabolic engineering expertise enables a broad range of bio-based chemicals to be commercialized rapidly and produced cost-effectively through precision fermentation.
RECENT NEWS
Subsequent Close of Series B Financing, Total Raised $39 million
31 January 2022 – DMC Biotechnologies, Inc. announces that strategic investors Continental Grain Company, through their venture arm Conti Ventures, and Toyobo have joined the Series B fundraising round, bringing the total raised to $39 million. DMC previously...
DMC Appoints Ashley Jenkins as CFO
5 January 2022 – DMC Biotechnologies has appointed Ashley Jenkins as Chief Financial Officer (CFO). Ashley joins DMC from Felix Energy where she has worked since 2013. Ashley joins DMC’s Boulder, Colorado office. Ashley Jenkins…
DMC Announces First Close of Series B Financing, Raising $34 million
2 December 2021 – DMC Biotechnologies has completed the first close of its Series B fundraising, raising $34 million (USD) with investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy…
DMC’s Downstream Processing Proven At Scale
13 May 2021 – DMC Biotechnologies has completed downstream processing for its first product, the amino acid L-alanine. The downstream processing was done at EW Biotech in Leuna, Germany following the successful demonstration of…
INVESTORS
